Pharma & Biotech VC & Investment News
Biotechnology
US clinical-stage biotech Apogee Therapeutics today announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart. 27 May 2026
Today's issue
Refine search
Biotechnology
US cell therapy manufacturing company Cellares has secured a $20 million investment from Cathie Wood’s ARK Invest, raising its Series D financing to $277 million and adding a high-profile backer as it scales its automated production network. 9 June 2026
Biotechnology
US biotech City Therapeutics has raised $99.5 million in a series B financing, giving the young RNA interference specialist more room to advance its pipeline and refine its next-generation RNAi engineering platform. 9 June 2026
Biotechnology
Parabilis Medicines announced today that it plans to raise up to $475 million through a US initial public offering. The biopharmaceutical company filed to offer 25 million shares priced between $17 and $19 each. 5 June 2026
Pharmaceutical
Spanish biotech Ona Therapeutics has raised $87 million in an oversubscribed series B round, giving the Barcelona company the cash to move its lead antibody-drug conjugate, ONA-255, into human studies. 4 June 2026
Pharmaceutical
US biotech NewLimit has raised $435 million in a series C round as it prepares to take its first age-reprogramming medicine into human trials next year. 3 June 2026
Biotechnology
USA-based rare disease biotech Rallybio has agreed to acquire privately-held Avenzo Therapeutics in a reverse merger that will shift the public company’s focus to oncology. 2 June 2026
Biotechnology
Cambridge, USA-based Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced the closing of a $32.5 million Series A financing. 1 June 2026
Biotechnology
US biotech Secretome Therapeutics has raised $30 million in series A financing from RA Capital Management, giving the Texan company fresh backing for a neonatal cardiac cell therapy pipeline led by STM-01. 28 May 2026
Biotechnology
Early-stage Swiss biotech BLEEDnFIRE Therapeutics (BnF), specializing in differentiated first-in-class RNA therapies for rare bleeding disorders, today announces its launch, having secured non-dilutive funding from Innosuisse, Venture Kick, the Gebert Rüf Foundation Innobooster program and Kickfund. 27 May 2026
Biotechnology
US clinical-stage biotech Apogee Therapeutics today announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart. 27 May 2026
Biotechnology
US clinical-stage biotech Cartesian Therapeutics today announced that it has entered into an agreement with K2 HealthVentures (K2HV), an alternative investment firm that provides flexible, long-term financing solutions in life sciences, to provide a credit facility of up to $150 million including an initial $50 million tranche. 26 May 2026
Biotechnology
USA-based Immix Biopharma, a global leader in AL amyloidosis, has announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a public price of $8.94 per share. 26 May 2026
Biotechnology
California-based biotech Assembly Biosciences’ climbed 9.4% to $29.00 mid mid-morning, after it announced the pricing of an underwritten, registered offering of common stock and pre-funded warrants, expected to generate approximately $100 million in gross proceeds. 22 May 2026
Biotechnology
French clinical-stage biotech Nanobiotix has announced the pricing of its previously announced global follow-on offering of 98.6 million euros ($114.4 million), sending the firm’s shares up 8.6% to 3.40 euros in early trading. 22 May 2026
Pharmaceutical
European healthcare investor GHO Capital and Asian healthcare-focused asset manager CBC Group have agreed to combine operations in a deal that will create what the companies describe as the world’s largest dedicated healthcare investment manager. 21 May 2026
Pharmaceutical
For much of the past decade, biotech companies sold investors on scale and future potential. Discovery engines, synthetic biology platforms, gene-editing systems and AI-led pipelines were presented as technologies capable of generating entire portfolios of medicines over time. The investment case often depended less on one product than on the promise that a platform could repeatedly produce new ones. 21 May 2026
Biosimilars
Olayan Financing Company (OFC) has made a minority equity investment in Jordan-headquartered MS Pharma, a leading pharma player in the Middle East North Africa (MENA) region that specializes in the development, production and distribution of a broad portfolio of generic and biologic therapies. 20 May 2026
Biotechnology
Texas, USA-based clinical-stage biotech Oorja Bio has announced the company’s launch and $30 million in Series A financing from its founding investor, Westlake BioPartners. 20 May 2026
Biotechnology
Canadian biotech InMed Pharmaceuticals is set to merge with privately held Mentari Therapeutics in an all-stock reverse merger that will create a Nasdaq-listed company focused on next-generation migraine prevention therapies. 20 May 2026
Biotechnology
Accro Bioscience, a Chinese biotech developing novel therapeutics that target molecular mechanisms of regulatory cell death for immune-mediated diseases, has announced the closing of its $50 million Series C financing. 19 May 2026
Biotechnology
US cell therapy manufacturing company Cellares has secured a $20 million investment from Cathie Wood’s ARK Invest, raising its Series D financing to $277 million and adding a high-profile backer as it scales its automated production network. 9 June 2026
Biotechnology
US biotech City Therapeutics has raised $99.5 million in a series B financing, giving the young RNA interference specialist more room to advance its pipeline and refine its next-generation RNAi engineering platform. 9 June 2026
Biotechnology
Parabilis Medicines announced today that it plans to raise up to $475 million through a US initial public offering. The biopharmaceutical company filed to offer 25 million shares priced between $17 and $19 each. 5 June 2026
Pharmaceutical
Spanish biotech Ona Therapeutics has raised $87 million in an oversubscribed series B round, giving the Barcelona company the cash to move its lead antibody-drug conjugate, ONA-255, into human studies. 4 June 2026
Pharmaceutical
US biotech NewLimit has raised $435 million in a series C round as it prepares to take its first age-reprogramming medicine into human trials next year. 3 June 2026
Biotechnology
USA-based rare disease biotech Rallybio has agreed to acquire privately-held Avenzo Therapeutics in a reverse merger that will shift the public company’s focus to oncology. 2 June 2026
Biotechnology
Cambridge, USA-based Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced the closing of a $32.5 million Series A financing. 1 June 2026
Biotechnology
US biotech Secretome Therapeutics has raised $30 million in series A financing from RA Capital Management, giving the Texan company fresh backing for a neonatal cardiac cell therapy pipeline led by STM-01. 28 May 2026
Biotechnology
Early-stage Swiss biotech BLEEDnFIRE Therapeutics (BnF), specializing in differentiated first-in-class RNA therapies for rare bleeding disorders, today announces its launch, having secured non-dilutive funding from Innosuisse, Venture Kick, the Gebert Rüf Foundation Innobooster program and Kickfund. 27 May 2026
Biotechnology
US clinical-stage biotech Apogee Therapeutics today announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart. 27 May 2026
Biotechnology
US clinical-stage biotech Cartesian Therapeutics today announced that it has entered into an agreement with K2 HealthVentures (K2HV), an alternative investment firm that provides flexible, long-term financing solutions in life sciences, to provide a credit facility of up to $150 million including an initial $50 million tranche. 26 May 2026
Biotechnology
USA-based Immix Biopharma, a global leader in AL amyloidosis, has announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a public price of $8.94 per share. 26 May 2026
Biotechnology
California-based biotech Assembly Biosciences’ climbed 9.4% to $29.00 mid mid-morning, after it announced the pricing of an underwritten, registered offering of common stock and pre-funded warrants, expected to generate approximately $100 million in gross proceeds. 22 May 2026
Biotechnology
French clinical-stage biotech Nanobiotix has announced the pricing of its previously announced global follow-on offering of 98.6 million euros ($114.4 million), sending the firm’s shares up 8.6% to 3.40 euros in early trading. 22 May 2026
Pharmaceutical
European healthcare investor GHO Capital and Asian healthcare-focused asset manager CBC Group have agreed to combine operations in a deal that will create what the companies describe as the world’s largest dedicated healthcare investment manager. 21 May 2026
Pharmaceutical
For much of the past decade, biotech companies sold investors on scale and future potential. Discovery engines, synthetic biology platforms, gene-editing systems and AI-led pipelines were presented as technologies capable of generating entire portfolios of medicines over time. The investment case often depended less on one product than on the promise that a platform could repeatedly produce new ones. 21 May 2026
Biosimilars
Olayan Financing Company (OFC) has made a minority equity investment in Jordan-headquartered MS Pharma, a leading pharma player in the Middle East North Africa (MENA) region that specializes in the development, production and distribution of a broad portfolio of generic and biologic therapies. 20 May 2026
Biotechnology
Texas, USA-based clinical-stage biotech Oorja Bio has announced the company’s launch and $30 million in Series A financing from its founding investor, Westlake BioPartners. 20 May 2026
Biotechnology
Canadian biotech InMed Pharmaceuticals is set to merge with privately held Mentari Therapeutics in an all-stock reverse merger that will create a Nasdaq-listed company focused on next-generation migraine prevention therapies. 20 May 2026
Biotechnology
Accro Bioscience, a Chinese biotech developing novel therapeutics that target molecular mechanisms of regulatory cell death for immune-mediated diseases, has announced the closing of its $50 million Series C financing. 19 May 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze